Taveras Arthur 4
4 · X4 Pharmaceuticals, Inc · Filed Mar 11, 2024
Insider Transaction Report
Form 4
Taveras Arthur
Chief Scientific Officer
Transactions
- Sale
Common Stock
2024-03-11$0.88/sh−14,235$12,552→ 234,301 total
Footnotes (2)
- [F1]Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.863 to $0.9112, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.